contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-healths-annual-report-for-financial-year-2021-2022-has-been-published

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

The discussion is quiet, but the company is quiet too.  The shareholder update is also quiet; someone from Nordea’s funds has sold a tiny bit, otherwise the top 100 practically hold onto their portfolios with white knuckles.  By the way, I spot about 15 company employees, managers, or board members on the lists, and they likewise hold onto their shares month after month. Perhaps I can also continue patiently, after all, Rome wasn’t built in a day.

Peculiar publication method. It has not been peer-reviewed, the models have been concealed, and the disclosures are brief (who really funded it). Nurses are no longer needed..

The mentioned CMD interventions and their assumed effects were included here. In the model, the nurse’s working time per patient was cut from 60 min to 10 min, meaning that during those 10 min, not much else can be done than probably checking the NG test results and booking an appointment with a doctor or for another intervention if risks are elevated. Here, only CMD and T2D diseases were discussed, so measuring other disease risks could, of course, bring additional benefits or harms regarding the NG test.  In occupational health, these are done, and in the public sector, at least health checks for the unemployed are done. The model assumed that 15.2% of 50–54 year olds would attend a health check annually. The ‘no health check’ branch would have been an interesting addition to the study; currently, there is no information on the incremental benefit compared to it.

I’m a bit at the edge of my understanding, so I ask if only the effect of CMD interventions is included in that QALY calculation, and would the nurse’s work with current methods be greater than calculated if other risk assessments were done (more forms to fill out?), but in NG’s test, would including those other chronic diseases as a basis for intervention not increase the cost side, even though it could increase the QALY side? And also, was it the case that these are not done much now because the nurses’ workload is too great relative to the benefit, i.e., how much would the adoption of NG’s test increase QALY vs. not doing it at all?

This is quite an interesting article. What caught my eye was that the logistic regression models used by Nightingale in the article were amusingly named “AI models,” which perhaps I should start using in my own publications. In a sense, it’s true if one interprets an AI model very broadly. In the publication, health check-ups primarily refer to those conducted by occupational health nurses in occupational health services, and the potential intervention chain that might follow, where those at high risk can see a doctor who may prescribe various interventions. It’s worth noting that almost all savings and cost-effectiveness come from discontinuing the nurses’ work and replacing it with Nightingale’s blood test and risk tests.  In the public sector, health check-ups have largely been discontinued as ineffective, so savings in that regard have already been realized. Health check-ups would not necessarily need to be replaced by anything (e.g., NG’s test); they could simply be stopped, which would itself be cost-effective and lead to significant savings. Here, savings have primarily been achieved by automating the work done by nurses, which could, of course, be valuable. The article’s simulation is quite well done, even though it uses “synthetic data,” which may not always increase credibility. This study has particularly well considered what such risk testing could lead to and modeled various common interventions that could follow different risk levels (here, for example, intervention for smoking cessation, tightening blood pressure or cholesterol targets, weight loss coaching) and given the effects on their realization. Finally, after applying all these to those at elevated risk and replacing current health check-ups with Nightingale’s test, the remaining expected quality-adjusted life years (QALY) for cohort members increase from 31.4 to 31.5 in scenarios 1 and 2, and correspondingly decrease by 0.01 years in scenario 3 .   At the population level, the changes achieved in quality-adjusted life years are in the order of a few per mille, i.e., insignificant, but the article appears to be the first to consider that testing with Nightingale’s test could also worsen people’s health and life expectancy at the population level, i.e., compared to the current operating model, which involves a nurse’s appointment where FINRISK and FINDRISC are performed. This, in my opinion, is the most interesting aspect of the article; it’s a shame that the authors do not elaborate on it further in the text or supplementary materials. It is only stated that there are differences in classification compared to the control group, and later there is talk of “inaccuracies” and classification ability of NG’s metabolomics modeling, which is further mentioned as being “slightly weaker” than presented in previous studies.  However, there are also several limitations. First, there are some inaccuracies remaining in the modelling of the MRS risk of individuals and modelled parametric disease-free survival times (i.e. the ability of MRS to recognize the ones in true risk seems to be a bit weaker in our model than reported in previous studies [13,14]). This makes the results presented weaker than they ought to be.  This could have been elaborated on more, but the main focus of this study seemed to be to evaluate the effects of NG’s test on costs and workloads, and it is stated in passing that these are significant and worthwhile despite potential negative health effects. One can certainly lobby for an issue this way, but one must also consider what it means for NG’s investment case if one pivots to talking only about cost-effectiveness and forgets about health effectiveness. Of course, even this study does not actually say whether NG’s test worsens or improves people’s health. The results are vague, fall within the margin of error, and were generated with synthetic data and a thousand assumptions. Transparency is poor. But the classification ability of NG tests is very poorly described and especially validated, and even here, worrying inaccuracies were referred to.

The savings achieved would be absolutely huge. And this is calculated only for cardiovascular diseases. NOTE! This is a Preprint article funded by NG and has not yet been published in a peer-reviewed journal. Also available as PDF here: https://www.medrxiv.org/content/10.1101/2025.09.11.25335561v1.full-text Image taken from Minja Salmio’s presentation at the German conference (https://youtu.be/pqiLqAX7UJI?si=x-1VrauFBOqQoW40)

Innoquest Pathology (parent company of diagnostics) has been operating there in Malaysia for 30 years and is the country’s leading diagnostics company. 5 million customers per year. NG has gained a good partner. I wouldn’t be surprised if the opening of a local lab there was announced soon. https://www.innoquest.com.my/about-us/?utm_source=chatgpt.com

Nightingale Health

Company release, 27 October 2022 at 11.25 p.m. (EEST)Nightingale Health Plc's Annual Report for financial year 1 July 2021-30 June 2022 has been published. The publication includes the Board...

Company release, 27 October 2022 at 11.25 p.m. (EEST)Nightingale Health Plc's Annual Report for financial year 1 July 2021-30 June 2022 has been published. The publication includes the Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report.The Annual Report, Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report are attached to this release and are also available on Nightingale Health's website at www.nightingalehealth.com/investors/.Nightingale Health will publish the Auditor's Report to the Financial Statements at a later announced date approximately within a week. The Auditor's Report is expected to be unqualified. The Auditor's Report is released after the release of the Financial Statements due to the transition to report in accordance with the International Financial Reporting Standards ("IFRS") instead of the Finnish Accounting Standards ("FAS") as of the financial year ended on 30 June 2022, which has caused a delay in the release schedule of the Auditor's Report.For further information, please contact:Teemu Suna, CEOir[at]nightingalehealth.comCertified Adviser: Oaklins Merasco Ltd, tel. +358 9 6129 670About Nightingale HealthNightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.Attachments:Annual Report 2021-2022Board of Directors' Report and Consolidated and Parent Company Financial Statements 2021-2022Corporate Governance Statement 2021-2022Remuneration Report 2021-2022